Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2008
04/01/2008US7351734 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
04/01/2008US7351733 Tetrahydrocarbazole derivatives and their pharmaceutical use
04/01/2008US7351732 Serotonin (5-hydroxytriptamine, 5-HT) 5-HT1A receptor subtype agonists; neuroprotective agents; cerebral damage due to traumatic or ischemic stroke; 2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol
04/01/2008US7351731 Low toxicity; antifungal agents effective against life-threatening systemic mycoses caused by C. neoformans, Aspergillus species, Candida species; prevent the synthesis of ergosterol by inhibiting the enzyme lanosterol demethylase; N-myristoyl transferase inhibition; increased lipophilicity
04/01/2008US7351730 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
04/01/2008US7351729 JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
04/01/2008US7351728 peroxisome proliferator activated receptor modulators; diabetes mellitus; side effects reduction; 2-Methyl-2-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}propionic acid; Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis
04/01/2008US7351727 Inhibitors of 15-lipoxygenase
04/01/2008US7351726 Serine protease inhibitor; angiogenesis factor; antitumor agents; atherosclerosis; thrombosis; chronic obstructive pulmonary disorders; Alzheimer's disease; anticancer agents; antidiabetic agents; cardiovascular disorders
04/01/2008US7351725 For therapy of immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection
04/01/2008US7351724 fewer side effects; 2-keto-oxadiazole derivatives; 7-phenyl-1-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-heptan-1-one;
04/01/2008US7351723 aqueous solution with ethylenediaminetetraacetic acid and sodium hydroxide and, or sodium carbonate; regenerated for injection
04/01/2008US7351722 for the preventive or curative treatment of hepatocellular deficiency
04/01/2008US7351721 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
04/01/2008US7351720 chemokine receptor (CCR) inhibitors for treating allergic or inflammatory diseases such as asthma or rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases; 2-((p-fluorobenzyl)piperidinylmethyl)cyclohexylureas of given formula
04/01/2008US7351719 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
04/01/2008US7351718 Muscarinic receptor antagonists; longer duration of action; side effect reduction; high potency; chronic obstructive pulmonary disease; asthma; inhalation; 2-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide
04/01/2008US7351717 Substituted pyrrolidine and related compounds
04/01/2008US7351716 Dermatological preparations
04/01/2008US7351715 Unit dosage forms for the treatment of herpes simplex
04/01/2008US7351714 viral infections; lung tumor and gastric cancer; 7-2-(2-aminophenyldithio)phenyliminomethylcamptothecin
04/01/2008US7351713 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
04/01/2008US7351712 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
04/01/2008US7351711 Tricyclic indanyls as integrin inhibitors
04/01/2008US7351710 Solid N-Methyl-N-[3-[3-[2-thienylcarbonyl]pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide; X-ray powder diffraction pattern lacks discernible or sharp peaks
04/01/2008US7351709 Estrogen receptor ligands
04/01/2008US7351708 Pyrrolo [2,3-b] pyridine derivatives
04/01/2008US7351707 Spiroazacyclic compounds as monoamine receptor modulators
04/01/2008US7351706 Indol-3-yl-carbonyl-spiro-piperidine derivatives
04/01/2008US7351705 Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient
04/01/2008US7351704 Indazole-carboxamide compounds as 5-HT4 receptor agonists
04/01/2008US7351703 Which modulate the endogenous production of cyclic guanosine monophosphate (cGMP); for therapy and prophylaxis of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficency, thromboses, and/or atherosclerosis
04/01/2008US7351702 Caspase inhibitors and uses thereof
04/01/2008US7351701 Therapeutic compounds
04/01/2008US7351700 4-(2-Hexylsulfanyl-6-methyl-pyrimidin-4-ylmethyl)-morpholine; antidepressant, anxiolytic agent, cognition activator; epilepsy, schizophrenia, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain
04/01/2008US7351699 Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent
04/01/2008US7351698 Androgen receptor modulators and methods of use thereof
04/01/2008US7351696 Compounds
04/01/2008US7351695 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
04/01/2008US7351694 Diagnosis of prostate cancer; genetic engineered protein
04/01/2008US7351693 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof
04/01/2008US7351692 Method and composition for potentiating the antipyretic action of a nonopioid analgesic
04/01/2008US7351686 Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
04/01/2008US7351567 Enzymatic resolution of selective estrogen receptor modulators
04/01/2008US7351531 Molecules capable of binding to telomere and the like and method with the use of the same
04/01/2008US7351436 Caffeic acid, chlorogenic acid and ferulic acid, and esters or salts, and one or more of central nervous system stimulating components, food fibers, extracts of plants, organic acids or sugar alcohols
04/01/2008US7351431 Dissolved cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(alkanoyloxy)]platinum(II) in 2-methyl-2-propanol; stabile, easily handled injection; fine, homogenous suspension; controlled particle size distribution
04/01/2008US7351429 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient, excipient, binder, lubricant and coating agent; uniform in the content of a small amount of active ingredient, excellent light stability; anticholinergic activity on bladder and drug for pollakiuria and urinary incontinence
04/01/2008US7351427 Biodistribution and reduced side effects; for parenteral administration
04/01/2008US7351426 Polyester/cyanoacrylate tissue adhesive compositions
04/01/2008US7351422 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
04/01/2008US7351419 Prepared by mixing a lower hydrate of Cefdiner with an aqueous carrier; kits with instructions to mix with water for administration; storage stability
04/01/2008US7351417 Glycerin moisturizer, copolymer of (meth)acrylic acid and/or anhydride with minor amount of alkyl (meth)acrylate, and surfactants
04/01/2008US7351407 Administering agents such as GW-8510, purvalanol A, roscovitine to inhibit expression, signaling or biological functions of connective tissue growth factor
04/01/2008US7351404 Method of enhancing hair growth
04/01/2008US7351401 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
04/01/2008US7351399 Conversion by human liver microsomes to MPO3H2; hepatitis, cancer, liver fibrosis, malaria, other viral and parasitic infections, and metabolic diseases where the liver is responsible for the overproduction of the biochemical end product, diabetes; enhanced oral drug delivery
04/01/2008US7351397 Synergistic mixture of organosulfer compound and 6-hydroxychroman compound; radiolabelling efficiency and shelf-life of peptide and non-peptide radiopharmaceutical compositions may be significantly increased by addition of a stabilizing amount of a hydrophilic 6-hydroxy-chroman derivatives
04/01/2008US7350331 Method for producing metabolites from plants cultivated in soil-less medium
04/01/2008CA2530543C Illudin analogs as anti-tumor agents
04/01/2008CA2471952C Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
04/01/2008CA2446574C Liquid pharmaceutical composition
04/01/2008CA2432578C Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
04/01/2008CA2414320C Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
04/01/2008CA2384885C Particulate vitamin composition
04/01/2008CA2372614C Process and product for enhancing immune response in companion animal using a combination of antioxidants
04/01/2008CA2363990C Use of glycyrrhizin in the treatment of mastitis
04/01/2008CA2356240C Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
04/01/2008CA2356157C Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
04/01/2008CA2343299C Method for preventing or delaying catheter-based revascularization
04/01/2008CA2339004C Antioxidant composition and method of treating diseases using same
04/01/2008CA2332713C Hydroxamic acid derivatives as antibacterials
04/01/2008CA2303817C 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids
04/01/2008CA2299288C Non-steroidal antiinflammatory drug formulations for topical application to the skin
04/01/2008CA2298974C Thiazolobenzoheterocycles, preparation and medicines containing same
04/01/2008CA2294099C Absorption of minerals
04/01/2008CA2291074C Composition and method for enhancing transport across biological membranes
04/01/2008CA2288726C Eyedrops containing a loratadine metabolite
04/01/2008CA2279293C Hexahydroindenopyridine compounds having antispermatogenic activity
04/01/2008CA2149408C Compositions for curing affected abnormal tissues, method for the preparation thereof, and usage thereof
04/01/2008CA2145661C Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
03/2008
03/27/2008WO2008036980A1 Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
03/27/2008WO2008036967A2 Novel heterocyclic compounds as lasy activators
03/27/2008WO2008036966A2 Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders
03/27/2008WO2008036954A1 Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
03/27/2008WO2008036912A2 Compositions and methods for treating jellyfish stings
03/27/2008WO2008036858A2 Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
03/27/2008WO2008036843A2 Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
03/27/2008WO2008036841A2 Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
03/27/2008WO2008036835A2 Methods and compositions for upregulation of peroxiredoxin activity
03/27/2008WO2008036825A2 Duplex oligonucleotide complexes and methods for gene silencing by rna interference
03/27/2008WO2008036807A2 Tea-derived compostiions and methods of using same for cardiovascular health
03/27/2008WO2008036792A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
03/27/2008WO2008036759A1 Spiro benzazepines as vasopressin antagonists
03/27/2008WO2008036755A1 Spiro benzazepines used as vasopressin antagonists
03/27/2008WO2008036747A2 Composition and method for immunomodulation
03/27/2008WO2008036733A2 Methods for treatment of vesicle transport disorders
03/27/2008WO2008036715A1 Heterocyclic organic compounds
03/27/2008WO2008036653A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
03/27/2008WO2008036647A1 Antiviral compositions and use thereof